RT Journal Article
SR Electronic
T1 Angiogenesis in epithelian ovarian cancer
JF Molecular Pathology
JO Mol Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 348
OP 359
DO 10.1136/mp.55.6.348
VO 55
IS 6
A1 E S Bamberger
A1 C W Perrett
YR 2002
UL http://mp.bmj.com/content/55/6/348.abstract
AB Angiogenesis, the development of new blood vessels from the existing vasculature, is an essential component of solid tumour growth and metastasis. Several angiogenic factors are expressed by many tumours, suggesting that tumours promote their own vascularisation by activating the host endothelium. This review will discuss various angiogenic stimulators and inhibitors in epithelian ovarian cancer (EOC), including vascular endothelial growth factor and platelet derived endothelial cell growth factor/thymidine phosphorylase. The analysis of tumour vascularisation by microvessel density will also be discussed and the relevance of these markers of angiogenesis in the prognosis of EOC will be assessed.